Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

155
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
155
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

107
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
107
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

97
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
97
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

87
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
87
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

147
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
147
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

72
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Hospital Discharge Planning: Empirical Insights and Requirements of AI-Based Technologies From an Explorative Mixed Methods Field Study.

JMIR formative research·2026
Same author

Testing a digitally administered intervention to increase social participation, physical fitness, and health awareness among healthy older adults by means of tablet-based app use: study protocol of the SMART-AGE randomized controlled trial.

Trials·2026
Same author

Left atrial appendage occlusion in vulnerable oldest-old patients - Effectiveness and safety in a large single-center registry.

Journal of the neurological sciences·2025
Same author

[Renal failure and drug-drug interactions].

MMW Fortschritte der Medizin·2024
Same author

Outbreak of SARS-CoV-2 in a geriatric acute-care ward during summer 2023: current aspects of infection control in the postpandemic period.

GMS hygiene and infection control·2024
Same author

[Anticoagulation in older patients].

Deutsche medizinische Wochenschrift (1946)·2023

Related Experiment Video

Updated: Nov 23, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

660

[How to manage polypharmacia?]

Heinrich Burkhardt

    Deutsche Medizinische Wochenschrift (1946)
    |January 4, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Managing polypharmacy requires more than counting drugs. An individualized approach, considering patient vulnerability and life stage, is crucial for optimizing risk-benefit in multimorbidity.

    More Related Videos

    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    19.2K
    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    10.9K

    Related Experiment Videos

    Last Updated: Nov 23, 2025

    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    660
    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    19.2K
    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    10.9K

    Area of Science:

    • Geriatric Medicine
    • Clinical Pharmacology
    • Health Services Research

    Background:

    • Polypharmacy presents a significant challenge in modern medicine, exacerbated by an aging population and increasing therapeutic complexity.
    • While drug count correlates with risk, solely focusing on the number of prescribed drugs or deprescribing is insufficient for managing polypharmacy.
    • Multimorbidity necessitates a nuanced understanding of patient-specific factors beyond drug quantity.

    Purpose of the Study:

    • To highlight the limitations of numerical analysis in polypharmacy and deprescribing.
    • To advocate for an individualized approach to optimize the risk-benefit ratio in patients with multimorbidity.
    • To introduce pattern analysis as a method for identifying vulnerable patients and high-risk polypharmacy patterns.

    Main Methods:

    • Review of current challenges in polypharmacy management.
    • Conceptual framework for individualized risk-benefit assessment.
    • Proposal of pattern analysis for patient and polypharmacy risk stratification.

    Main Results:

    • Numerical analysis alone is inadequate for addressing polypharmacy complexities.
    • Individualized approaches are essential for optimizing risk-benefit in multimorbidity.
    • Pattern analysis can identify vulnerable patients and high-risk polypharmacy combinations.

    Conclusions:

    • Effective polypharmacy management requires moving beyond simple drug counts.
    • An individualized strategy, incorporating patient vulnerability and life stage, is key.
    • Pattern analysis offers a promising tool for personalized medication review and deprescribing.